Durvalumab vs Montelukast

Durvalumab vs Montelukast: Overview

This comparison examines the pharmacological differences between Durvalumab and Montelukast.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Montelukast: Selective leukotriene D4 receptor antagonist.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Montelukast — 2.7-5.5 hours.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S.

Molecular Weight: Montelukast — 586.1800 g/mol.

Type: Durvalumab — Antibody; Montelukast — Small molecule.